MREO Class Action Alert: Deadline Approaches March 6, 2026!

Overview of the Class Action and Company Background

Mereo BioPharma Group plc (NASDAQ: MREO) is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases (www.globenewswire.com). The company is currently facing a securities class action lawsuit filed on behalf of investors who purchased Mereo’s American Depositary Shares (ADS) between June 5, 2023 and December 26, 2025 (www.globenewswire.com). The suit alleges that Mereo misled investors about the prospects of its lead drug candidate, setrusumab, during two Phase 3 trials for osteogenesis imperfecta (OI) (www.globenewswire.com). On December 29, 2025, Mereo announced that neither of its Phase 3 studies (ORBIT and COSMIC) met the primary endpoint of reducing fracture rates in OI patients (www.globenewswire.com). This unexpected trial failure caused MREO shares to plunge by over 87%, collapsing from $2.31 to about $0.29 in a single day (www.globenewswire.com). With shareholders incurring heavy losses, several law firms have issued “class action alert” notices. Lead plaintiff motions are due by early April 2026 (law firm notices cite an April 6, 2026 deadline) (nationaltoday.com), creating urgency for affected investors to consider their legal options. The class action and the steep stock drop underscore significant concerns around Mereo’s disclosures and future prospects.

Dividend Policy and History

Mereo BioPharma has no history of paying dividends, which is typical for a clinical-stage biotech that generates no product revenue. In fact, the company explicitly states it “has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends in the foreseeable future” (www.sec.gov). All available capital is reinvested to fund drug development rather than shareholder payouts (www.sec.gov). As a result, MREO’s dividend yield is 0%, and investors seeking returns have to rely on stock price appreciation (or recovery) driven by clinical success. Traditional REIT metrics like AFFO or FFO are not applicable here – Mereo is a pre-revenue biotech with negative earnings (for example, it reported zero revenues in recent periods) (www.mereobiopharma.com). The absence of any dividend highlights management’s prioritization of R&D investment over shareholder cash returns, which is sensible given the company’s stage and need for funding. However, it also means shareholders do not receive any direct income while waiting for the pipeline to (hopefully) create value.

Financial Position: Leverage, Liquidity, and Coverage

Leverage: Mereo carries minimal debt, leaning on equity financing and partnerships to fund operations. The company previously had a credit facility with Silicon Valley Bank and Kreos Capital, but that loan has since been repaid or terminated. As of the end of 2022, the former lenders held only warrants to purchase Mereo shares – indicating the debt itself was retired (www.sec.gov). In other words, Mereo has no significant interest-bearing debt outstanding at present, and thus financial leverage is very low. This capital structure spares the company from near-term debt maturities and interest obligations that could strain its limited resources.

Liquidity: Mereo’s liquidity comes from its cash reserves, bolstered in part by past equity raises and collaboration payments. The company reported cash and cash equivalents of $48.7 million as of September 30, 2025 (www.mereobiopharma.com). Management affirmed that, based on current operating plans, this cash should be sufficient to support operations into 2027 (www.mereobiopharma.com) (www.mereobiopharma.com). The cash runway projection suggests at least ~2 years of funding remained prior to the recent trial failure. Notably, immediately after the disappointing Phase 3 results, management moved to “carefully manage [its] cash resources with immediate reductions in pre-commercial and manufacturing activities” (www.globenewswire.com). These cost-cutting steps could further extend the runway. Additionally, Mereo has monetized assets through partnerships – for instance, it received a $50 million upfront payment from Ultragenyx in 2021 for the setrusumab collaboration (www.sec.gov). Overall, liquidity appears adequate in the near term, but the outlook beyond 2026 will depend on R&D spending and any new funding or partnership inflows.

Coverage: With effectively no debt, traditional interest coverage ratios are a non-issue (there are no interest payments to “cover”). The more relevant coverage consideration is whether the existing cash can cover the company’s ongoing operating losses. Mereo remains unprofitable, as is common for clinical biotechs – it incurred a net loss of about $7.0 million in Q3 2025 (narrower than the $15.0 million loss in Q3 2024) (www.mereobiopharma.com). For the first nine months of 2025, cumulative loss was $34.5 million (www.mereobiopharma.com), reflecting the substantial R&D and trial costs. Based on this burn rate (roughly $10–15 million per quarter recently), $48.7 million in cash would cover roughly 4–6 quarters of operation. Management’s guidance that cash lasts into 2027 implies either a planned reduction in expenses or expectation of additional cash inflows to bridge the gap (www.mereobiopharma.com). Encouragingly, Mereo has no outstanding loans or coupon payments, so every dollar of cash can go directly toward R&D and operating needs rather than debt service. The key coverage ratio to monitor is cash-to-burn: if pipeline activities accelerate (e.g. starting a new Phase 3 trial) or if unexpected costs arise, the company may need more capital before 2027. In summary, current cash on hand appears to cover Mereo’s near-term needs, but the company’s ability to sustain itself long term will require either pipeline success leading to new partnerships/milestones or external financing.

Valuation and Comparables

Mereo’s market valuation has been severely impacted by the recent clinical setback. After the Phase 3 trial failures announced in late 2025, MREO’s share price imploded by over 90% (www.tipranks.com). The stock fell from the ~$2–3 range to mere pennies on the dollar – trading around $0.30–$0.40 per share in early 2026 (www.tipranks.com) (www.marketscreener.com). As of late February 2026, MREO was quoted near $0.40 on NASDAQ (www.marketscreener.com). At this depressed price, the company’s market capitalization is roughly $60 million, only slightly above its last reported cash balance (~$49 million as of Q3 2025) (www.mereobiopharma.com). In effect, the market is valuing Mereo’s drug pipeline and other assets at close to zero – or even at a negative implied value once liabilities are considered. This phenomenon (a biotech trading at or below cash-on-hand) reflects extreme skepticism from investors regarding the company’s ability to create future value with its remaining pipeline. It is reminiscent of late 2022, when an activist investor pointed out that Mereo’s stock was valued at less than half of net cash, implying a negative NPV for its programs at that time (www.businesswire.com).

Traditional valuation metrics like price-to-earnings or price-to-FFO are not meaningful for MREO, as the company has no earnings or FFO to speak of (no approved products and essentially zero revenue) (www.mereobiopharma.com). Instead, biotech investors often value companies on measures such as cash per share, pipeline prospects, or probabilities of drug approval. By cash per share metrics, MREO’s valuation is near liquidation value. By pipeline metrics, the current sub-$1 stock price suggests the market has written off setrusumab’s prospects and is highly uncertain about the remaining programs.

For context, sell-side analysts (before the trial failure) had been relatively bullish on Mereo. As recently as Q4 2025, the stock held a consensus “Strong Buy” rating from analysts, with an average price target of about $6.67 per share (www.tipranks.com). That optimistic target implied a massive upside from pre-crash trading levels. Obviously, those targets will be re-evaluated given the new reality. If any analysts update their models now, valuations would likely emphasize the value of Mereo’s cash plus a deeply risk-adjusted (or zero) value for setrusumab, plus some value for its other asset alvelestat. Comparable small-cap rare disease biotech companies with late-stage failures often trade at or below cash value, unless a credible new path to value emerges. In summary, MREO appears “option value” priced – the stock reflects the cash safety net, with a essentially a low-cost option on future pipeline success. Any signs of a turnaround (such as a new partnership or positive trial data in another program) could rerate the stock upward, whereas continued setbacks or cash burn without progress could put further pressure on the valuation.

Key Risks and Red Flags

Investing in Mereo BioPharma entails substantial risks, especially in light of recent events and the company’s profile:

– Clinical and Pipeline Risk: Mereo is heavily dependent on a few drug candidates, and their success is uncertain. The company itself has acknowledged that it depends “heavily on the success of setrusumab, alvelestat and etigilimab” and cannot assure that any of these will achieve their desired outcomes (www.sec.gov). This concentration risk became evident when setrusumab’s Phase 3 results failed – wiping out a major portion of Mereo’s development pipeline in one blow. The remaining pipeline (such as alvelestat for alpha-1 antitrypsin deficiency lung disease) is still in development and must now shoulder the burden of restoring shareholder value. If alvelestat or other programs were to face setbacks, Mereo would be left with very few alternatives. The binary, high-risk nature of drug trials means the stock will likely remain volatile and could fall further on additional bad news.

– No Revenue & Need for Funding: Mereo has no approved products generating revenue, and the company continues to incur significant operating losses (www.mereobiopharma.com) (www.mereobiopharma.com). It relies on external financing (equity issuances, partnerships, or licensing deals) to fund R&D. This model carries the risk of dilution or financial strain. The management has warned that if they cannot raise additional capital when needed, they may be forced to “delay, limit, reduce, or terminate” development programs (www.sec.gov). While current cash will sustain the company for a while, launching a new Phase 3 trial (e.g. for alvelestat) could quickly escalate cash burn. There is a real risk of future dilution: if Mereo’s share price remains very low, any new equity raise would severely dilute existing shareholders. The alternative – taking on debt – is usually not feasible for a clinical-stage biotech without cash flow. This financing risk is compounded by the recent stock drop, which weakens the company’s bargaining position for both fundraises and partnerships.

– Regulatory and Listing Compliance Risk: MREO is now a penny stock (trading well below $1), which raises concerns about continued NASDAQ listing compliance. In fact, Mereo received a Nasdaq notice in late 2022 for failing to maintain the $1.00 minimum bid price (www.sec.gov), though it later regained compliance (potentially helped by positive developments or corporate actions). With shares back under $0.50, the company could again face delisting risk if the price doesn’t recover above $1. Nasdaq’s rules typically allow 180 calendar days to cure such a deficiency (www.sec.gov). If Mereo cannot lift its share price (through market appreciation or a reverse stock split) in the allotted time, it might be delisted to OTC markets, which would greatly reduce liquidity for shareholders. This adds pressure on management to improve the stock price or enact measures to consolidate shares.

– Legal and Governance Red Flags: The very fact that Mereo is subject to a shareholder class action is a red flag. The lawsuit alleges that company executives made materially misleading statements about the Phase 3 trials – painting an overly optimistic picture while concealing adverse facts (www.globenewswire.com). These claims, if true, suggest serious lapses in transparency and governance. Even if the class action is eventually dismissed or settled (common outcomes in biotech securities cases), the allegations can erode investor trust in management’s communications. Importantly, this isn’t the first time Mereo’s leadership has been accused of misleading shareholders. In 2022, Rubric Capital – a large 14% shareholder – engaged in a proxy battle and blasted Mereo’s “poor corporate governance” and “misleading public statements” by management (www.businesswire.com). That activism led to significant board turnover (four directors resigned and were replaced) and an agreement to refocus the company’s strategy (www.biospace.com). While Mereo’s board and management survived that episode, the recurrence of credibility issues in 2025 (with the trial communications) highlights ongoing governance concerns. Shareholders must weigh whether the current leadership is capable of successfully steering the company and being fully transparent about risks and progress.

– Partner and Concentration Risk: Mereo’s strategy involves partnering with larger pharma companies for development and commercialization (as seen with Ultragenyx for setrusumab and a newer partnership with āShibo for another asset). These partnerships can bring in non-dilutive capital and expertise, but they also cede some control. The setrusumab collaboration with Ultragenyx is a case in point – Ultragenyx ran the Phase 3 trials, and the outcome reflects on both companies. If partners decide to pull back (for example, Ultragenyx might reconsider further investment in setrusumab after the trial failure), Mereo could be left without the support needed to advance or commercialize a therapy. Dependence on partners means Mereo’s fate is not entirely in its own hands. On the other hand, the company’s ability to secure and maintain partnerships is crucial for its success – any breakdown in partner relationships or difficulty finding new partners for programs like alvelestat would be a negative signal.

In sum, Mereo is a high-risk, high-uncertainty stock. The combination of clinical uncertainty, financial dependency, governance flags, and legal overhang makes for a speculative situation. Investors should be prepared for potential further downside (e.g. if the class action or another issue uncovers damaging information, or if NASDAQ delisting becomes imminent) as well as the possibility of sharp upside on any positive surprise.

Open Questions and Outlook

Given Mereo’s precarious state, several open questions will determine its future trajectory:

– Can Setrusumab Be Salvaged? After the failure of the Phase 3 ORBIT and COSMIC trials in OI, Mereo’s flagship program is in jeopardy. Management expressed disappointment but indicated they will conduct additional analyses of the data “to assess next steps and the best path forward for the program, especially in pediatrics given the totality of the data and lack of other treatment options in OI” (www.globenewswire.com). This leaves an open question: Is there any viable path to salvage setrusumab (for example, focusing on a subgroup of pediatric patients or using bone density as a surrogate endpoint)? Or are the trial results definitive enough that the drug’s chances of approval are minimal? Ultragenyx, the development partner, has a stake in this decision as well. Investors will be watching for any announcements on whether further clinical development will continue (perhaps a smaller trial or extended analysis) or if the program will be shelved. The outcome will significantly affect Mereo’s long-term prospects – salvaging setrusumab could revive some of the lost value, whereas a complete termination would shift all hope to other assets.

– Will Mereo Secure a Partner or Funding for Alvelestat’s Phase 3? The next important asset in Mereo’s pipeline is alvelestat (MPH-966) for alpha-1 antitrypsin deficiency-related lung disease. The company has reported encouraging Phase 2 results in this indication and has aligned with regulators on Phase 3 trial design (www.mereobiopharma.com). Crucially, Mereo has been seeking a development/commercialization partner for alvelestat before launching Phase 3, to share costs and expertise (www.mereobiopharma.com). An open question is whether (and when) the company can lock in a partnership deal for alvelestat. A partnership could bring upfront cash and cover a substantial portion of Phase 3 expenses, extending Mereo’s cash runway and validating the drug’s potential. Conversely, if no partner is found in a reasonable time, Mereo might face a tough choice: either finance the Phase 3 on its own (at the risk of running out of cash or needing a huge capital raise) or delay/cancel the trial. The resolution of this question will shape 2026–2027 for Mereo. A positive partnership announcement would likely be a catalyst for the stock, whereas continued delays might signal that potential partners are unconvinced about alvelestat’s prospects or Mereo’s stability.

– What Are the Strategic Alternatives? With Mereo’s stock trading at distressed levels and the company’s pipeline narrowed, shareholders and the board will inevitably revisit the discussion of strategic alternatives. Back in 2022, Rubric Capital urged Mereo to actively consider alternatives to maximize shareholder value – essentially hinting at a sale, merger, or other corporate transactions – noting that the market was valuing Mereo below its cash value at the time (www.businesswire.com). Today, after the recent crash, Mereo is once again near net cash value. Will management consider a merger or sale of the company? For example, a larger biotech might find Mereo’s remaining assets (and cash) attractive enough to acquire at a premium to the current price. Alternatively, Mereo could seek to acquire or merge with another company to diversify its pipeline (a reverse merger, using its NASDAQ listing and cash as a vehicle). These possibilities are speculative, but given that an activist already pushed for such ideas once, and the board resisted at that time (www.businesswire.com), it remains an open question if circumstances have changed now. Any indication that Mereo’s board is exploring bids or strategic deals could significantly alter the investment outlook.

– How Will the Class Action Resolve? The ongoing class action lawsuit adds uncertainty. While securities class actions can take years to resolve, investors will want to know if there’s merit to the allegations of fraud or misrepresentation. An adverse outcome (for instance, discovery of intentional data misrepresentation) could further damage the company’s reputation or lead to financial penalties (though typically D&O insurance might cover settlements). On the flip side, if the case is dismissed or quietly settled, it might remove a layer of distraction for management. The lead plaintiff deadline in early April 2026 (nationaltoday.com) is the next immediate milestone; after that, the case will proceed through legal motions. This is an area to watch, but it’s largely out of the company’s control now.

– Can Management Rebuild Credibility? Mereo’s CEO, Dr. Denise Scots-Knight, and her team have been under intense scrutiny. Between the proxy fight in 2022 and the current lawsuit, management’s credibility has taken hits. An open question is whether the leadership can regain investor confidence. This could involve more conservative communication going forward, delivering on smaller milestones, or even bringing new blood into management or the board (to signal change). How the company communicates trial post-mortems, cash plans, and partnerships in the coming months will be key. Investors will be looking for transparency and realistic guidance from here on out.

Outlook: In the near term, MREO stock is likely to remain range-bound at low levels unless there is a tangible positive development. Potential upside catalysts include: a favorable partnership for alvelestat, any hint that setrusumab isn’t completely dead (for example, a regulatory discussion that yields a path forward), or corporate action like a takeover. Downside risks include: failure to secure a partner, running low on cash faster than expected, or NASDAQ delisting issues – any of which could further erode value. The risk/reward is extreme at this juncture. Some bottom-fishing investors might view Mereo as a deep-value speculation – the company does still have cash and a chance (albeit a smaller one) to create value with its remaining pipeline and partnerships. However, caution is warranted given the multitude of risks. Until more clarity emerges on the questions above, Mereo BioPharma faces a challenging road ahead. Each forthcoming development – whether clinical, legal, or strategic – will significantly sway the company’s fortunes and, by extension, its shareholders’ outcomes.

хайр (Prepared on behalf of: Unknown Publisher)

For informational purposes only; not investment advice.